CPRX vs IR · P/E 18, rev $491.7M vs P/E 49, rev $7.24B
Catalyst Pharmaceuticals Inc (CPRX) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
Catalyst Pharmaceuticals Inc (CPRX) is a biotechnology company listed on NASDAQ.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Latest reported CPRX revenue for 2024-12-31 was $491.7M. Net income was $163.9M. Revenue was up 23.5% from 2023-12-31 to 2024-12-31. CPRX currently screens at market cap $3.84B and trailing P/E 18.2.
Latest reported IR revenue for 2024-12-31 was $7.24B. Net income was $846.3M. Revenue was up 5.2% from 2023-12-31 to 2024-12-31. IR currently screens at market cap $28.27B and trailing P/E 48.8.
CPRX currently screens at market cap $3.84B and trailing P/E 18.2. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the CPRX and IR stock pages for the full models.
Not investment advice.